Floatz logo

SATOREOTIDE TRIZOXETAN

Small Cell Lung Cancer and Breast Cancer

Ipsenprotein_peptidePhase 1/2Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Small Cell Lung Cancer and Breast Cancer cohort.

Asset / SponsorPhaseRating
Satoreotide Tetraxetan
Ipsen
Phase 1/2NR

Same molecule, other indications

SATOREOTIDE TRIZOXETAN is also rated in:

digestive system neuroendocrine neoplasmDormant
CC
Indicative ·
41 / 100
View asset →
breast cancerDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →